Neoadjuvant and adjuvant therapy for renal cell carcinoma: critique, current trials and future directions
The following articles discuss the use of neoadjuvant therapy (drug [...]
Adjuvant therapy for high risk kidney cancer
Dr Umberto Capitanio from the Department of Urology, San Raffaele [...]
The impact of immunotherapy on the treatment of kidney cancer
Professor Thomas Powles, Barts Cancer Institute, London discusses the impact [...]
Sunitinib approved by the FDA for adjuvant treatment of advanced kidney cancer
The US Food and Drug Administration (FDA) has approved sunitinib [...]
Nivolumab improves survival of kidney cancer patients at three years
Updated results from the phase 3 CheckMate-025 study, presented at [...]
Tivozanib plus nivolumab combination shows promise
AVEO Oncology and EUSA Pharma have announced promising results from [...]
Nivolumab for the treatment of non-clear cell renal cell carcinoma
A retrospective study has proven the effectiveness and tolerability of [...]
First-line treatment for metastatic kidney cancer – an interview with Dr Eric Jonasch
The following is an interview with Dr Eric Jonasch, Professor [...]
Gut bacteria ‘boost’ cancer immunotherapy
Researchers from France and the USA have shown that the [...]
Nivolumab reduces brain metastases volume in some kidney cancer patients
A recent study by researchers from the Gustave Roussy Cancer Campus in [...]
